Pharvaris director sells 8,000 shares after option

Pharvaris director Robert Glassman completed a scheduled cashless option exercise and same‑day sale of 8,000 shares under a Rule 10b5‑1 plan.

Rhea-AI Filing Summary

Pharvaris N.V. (PHVS) reported that director Robert Glassman exercised options for 8,000 shares of common stock on September 9, 2026 at an exercise price of $20.00 per share and immediately sold 8,000 shares the same day. The transactions were carried out as a scheduled cashless exercise and sale under a Rule 10b5-1 trading plan, and the option grant covering these 8,000 shares is now fully exercised.

Insider Trade Summary 10b5-1

Exercise and Sale: 8,000 shares ($140K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Glassman Robert

Role Director

Sold 8,000 shs ($300K)

Approx. gross sale proceeds $300K

Approx. exercise cost $160K

Approx. pre-tax spread $140K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F3	8,000	$0.00	$0.00
Exercise	Common Stock F1	8,000	$20.00	$160K
Sale	Common Stock F1, F2	8,000	$37.5495	$300K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 10,500 shares (Direct)

Footnotes (3)

1. F1. This is a scheduled exercise and sale from 10b5-1 trading plan.
2. F2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $37.21 to $37.83. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
3. F3. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Shares exercised: 8,000 shares Option exercise price: $20.00 per share Shares sold: 8,000 shares +4 more

7 metrics

Shares exercised 8,000 shares Options for Pharvaris common stock exercised on September 9, 2026

Option exercise price $20.00 per share Exercise price for 8,000-share option exercised September 9, 2026

Shares sold 8,000 shares Common shares sold on September 9, 2026 following option exercise

Weighted average sale price $37.5495 per share Weighted average price for 8,000 shares sold September 9, 2026

Sale price range $37.21–$37.83 per share Range of prices for multiple sale transactions on September 9, 2026

Option expiration date February 5, 2031 Expiration date of the option that was exercised for 8,000 shares

Option vesting start February 5, 2022 Date when 25% of the option vested; balance in 48 monthly installments

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, cashless exercise transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The reported price represents a weighted average sale price ... pursuant to a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold in multiple transactions"

cashless exercise transaction financial

"The shares were sold in connection with the exercise of stock options in a cashless exercise transaction."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pharvaris N.V. (PHVS) disclose for Robert Glassman?

Pharvaris disclosed that director Robert Glassman exercised options for 8,000 shares of common stock at $20.00 per share on September 9, 2026 and sold 8,000 shares the same day in a cashless transaction under a Rule 10b5-1 trading plan.

How many Pharvaris (PHVS) shares did Robert Glassman sell and at what price?

Robert Glassman sold 8,000 shares of Pharvaris common stock on September 9, 2026 at a weighted average price of $37.5495 per share, with individual sale prices ranging from $37.21 to $37.83, as part of a cashless exercise and sale.

What options did Robert Glassman exercise in this Pharvaris (PHVS) Form 4?

He exercised stock options covering 8,000 shares of Pharvaris common stock at an exercise price of $20.00 per share. The option was originally scheduled to vest 25% on February 5, 2022, with the remaining shares vesting in equal monthly installments over 48 months.

Were Robert Glassman’s Pharvaris (PHVS) transactions under a Rule 10b5-1 plan?

Yes. The filing states that the exercise and sale on September 9, 2026 were a scheduled exercise and sale under a Rule 10b5-1 trading plan, and the document’s Rule 10b5-1 affirmation box is marked as applicable to these transactions.

Did this Pharvaris (PHVS) Form 4 report any remaining options from this grant for Robert Glassman?

No remaining options from this specific grant are reported. The filing shows options for 8,000 shares were exercised, and the entry for that option reflects 0 shares remaining from that grant after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 12:25 PM Accepted by SEC EDGAR 09/11/2026 - 12:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glassman Robert

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2026		M(1)		8,000	A	$20	18,500	D
Common Stock	09/09/2026		S(1)		8,000	D	$37.5495(2)	10,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20	09/09/2026		M			8,000	(3)	02/05/2031	Common Stock	8,000	$0	0	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $37.21 to $37.83. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Robert Glassman	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)